Anti-obesity and anti-inflammatory effects of macrophage-targeted interleukin-10-conjugated liposomes in obese mice

Riki Toita, Takahito Kawano, Masaharu Murata, Jeong Hun Kang

    研究成果: ジャーナルへの寄稿記事

    12 引用 (Scopus)

    抄録

    Obesity is associated with chronic inflammation and is known as a major risk factor for several diseases including chronic kidney disease, diabetes, and cardiovascular diseases. Macrophages play a critical role in the development of obesity-induced inflammation. Efficient delivery of therapeutic anti-inflammatory molecules, such as interleukin (IL)-10, to macrophages can dramatically improve therapeutic efficacy of obesity treatments. We used liposomes containing the ‘eat-me’ signal phosphatidylserine (PS) (PS-containing liposomes; PSL), which have macrophage targeting ability and anti-inflammatory functions, as a biomaterial carrier for the delivery of IL-10 to macrophages. The IL-10-conjugated PSL (PSL-IL10) showed high affinity for macrophages. In obese mice, PSL-IL10 treatment exhibited significant anti-obesity and anti-inflammatory effects, such as reduced serum total cholesterol, adipocyte size, crown-like structures, proinflammatory cytokine secretion (IL-6 and tumor necrosis factor α) in adipose tissue, liver injury, hepatic steatosis, and inflammation foci, while treatment with IL-10 or PSL alone did not. These findings suggest that the PSL-IL10 has macrophage targeting ability and enhanced anti-inflammatory effect due to the synergistic anti-inflammatory effects of IL-10 and PSL, and can be used as a macrophage-targeted therapeutic material for inflammation-related diseases, including obesity.

    元の言語英語
    ページ(範囲)81-88
    ページ数8
    ジャーナルBiomaterials
    110
    DOI
    出版物ステータス出版済み - 12 1 2016

    Fingerprint

    Obese Mice
    Liposomes
    Macrophages
    Interleukin-10
    Anti-Inflammatory Agents
    Obesity
    Inflammation
    Phosphatidylserines
    Therapeutics
    Cholesterol
    Medical problems
    Liver
    Biomaterials
    Biocompatible Materials
    Crowns
    Chronic Renal Insufficiency
    Adipocytes
    Adipose Tissue
    Interleukin-6
    Tissue

    All Science Journal Classification (ASJC) codes

    • Bioengineering
    • Ceramics and Composites
    • Biophysics
    • Biomaterials
    • Mechanics of Materials

    これを引用

    Anti-obesity and anti-inflammatory effects of macrophage-targeted interleukin-10-conjugated liposomes in obese mice. / Toita, Riki; Kawano, Takahito; Murata, Masaharu; Kang, Jeong Hun.

    :: Biomaterials, 巻 110, 01.12.2016, p. 81-88.

    研究成果: ジャーナルへの寄稿記事

    Toita, Riki ; Kawano, Takahito ; Murata, Masaharu ; Kang, Jeong Hun. / Anti-obesity and anti-inflammatory effects of macrophage-targeted interleukin-10-conjugated liposomes in obese mice. :: Biomaterials. 2016 ; 巻 110. pp. 81-88.
    @article{00ef9fe1b71d4d64b390dbaa66fdbd16,
    title = "Anti-obesity and anti-inflammatory effects of macrophage-targeted interleukin-10-conjugated liposomes in obese mice",
    abstract = "Obesity is associated with chronic inflammation and is known as a major risk factor for several diseases including chronic kidney disease, diabetes, and cardiovascular diseases. Macrophages play a critical role in the development of obesity-induced inflammation. Efficient delivery of therapeutic anti-inflammatory molecules, such as interleukin (IL)-10, to macrophages can dramatically improve therapeutic efficacy of obesity treatments. We used liposomes containing the ‘eat-me’ signal phosphatidylserine (PS) (PS-containing liposomes; PSL), which have macrophage targeting ability and anti-inflammatory functions, as a biomaterial carrier for the delivery of IL-10 to macrophages. The IL-10-conjugated PSL (PSL-IL10) showed high affinity for macrophages. In obese mice, PSL-IL10 treatment exhibited significant anti-obesity and anti-inflammatory effects, such as reduced serum total cholesterol, adipocyte size, crown-like structures, proinflammatory cytokine secretion (IL-6 and tumor necrosis factor α) in adipose tissue, liver injury, hepatic steatosis, and inflammation foci, while treatment with IL-10 or PSL alone did not. These findings suggest that the PSL-IL10 has macrophage targeting ability and enhanced anti-inflammatory effect due to the synergistic anti-inflammatory effects of IL-10 and PSL, and can be used as a macrophage-targeted therapeutic material for inflammation-related diseases, including obesity.",
    author = "Riki Toita and Takahito Kawano and Masaharu Murata and Kang, {Jeong Hun}",
    year = "2016",
    month = "12",
    day = "1",
    doi = "10.1016/j.biomaterials.2016.09.018",
    language = "English",
    volume = "110",
    pages = "81--88",
    journal = "Biomaterials",
    issn = "0142-9612",
    publisher = "Elsevier BV",

    }

    TY - JOUR

    T1 - Anti-obesity and anti-inflammatory effects of macrophage-targeted interleukin-10-conjugated liposomes in obese mice

    AU - Toita, Riki

    AU - Kawano, Takahito

    AU - Murata, Masaharu

    AU - Kang, Jeong Hun

    PY - 2016/12/1

    Y1 - 2016/12/1

    N2 - Obesity is associated with chronic inflammation and is known as a major risk factor for several diseases including chronic kidney disease, diabetes, and cardiovascular diseases. Macrophages play a critical role in the development of obesity-induced inflammation. Efficient delivery of therapeutic anti-inflammatory molecules, such as interleukin (IL)-10, to macrophages can dramatically improve therapeutic efficacy of obesity treatments. We used liposomes containing the ‘eat-me’ signal phosphatidylserine (PS) (PS-containing liposomes; PSL), which have macrophage targeting ability and anti-inflammatory functions, as a biomaterial carrier for the delivery of IL-10 to macrophages. The IL-10-conjugated PSL (PSL-IL10) showed high affinity for macrophages. In obese mice, PSL-IL10 treatment exhibited significant anti-obesity and anti-inflammatory effects, such as reduced serum total cholesterol, adipocyte size, crown-like structures, proinflammatory cytokine secretion (IL-6 and tumor necrosis factor α) in adipose tissue, liver injury, hepatic steatosis, and inflammation foci, while treatment with IL-10 or PSL alone did not. These findings suggest that the PSL-IL10 has macrophage targeting ability and enhanced anti-inflammatory effect due to the synergistic anti-inflammatory effects of IL-10 and PSL, and can be used as a macrophage-targeted therapeutic material for inflammation-related diseases, including obesity.

    AB - Obesity is associated with chronic inflammation and is known as a major risk factor for several diseases including chronic kidney disease, diabetes, and cardiovascular diseases. Macrophages play a critical role in the development of obesity-induced inflammation. Efficient delivery of therapeutic anti-inflammatory molecules, such as interleukin (IL)-10, to macrophages can dramatically improve therapeutic efficacy of obesity treatments. We used liposomes containing the ‘eat-me’ signal phosphatidylserine (PS) (PS-containing liposomes; PSL), which have macrophage targeting ability and anti-inflammatory functions, as a biomaterial carrier for the delivery of IL-10 to macrophages. The IL-10-conjugated PSL (PSL-IL10) showed high affinity for macrophages. In obese mice, PSL-IL10 treatment exhibited significant anti-obesity and anti-inflammatory effects, such as reduced serum total cholesterol, adipocyte size, crown-like structures, proinflammatory cytokine secretion (IL-6 and tumor necrosis factor α) in adipose tissue, liver injury, hepatic steatosis, and inflammation foci, while treatment with IL-10 or PSL alone did not. These findings suggest that the PSL-IL10 has macrophage targeting ability and enhanced anti-inflammatory effect due to the synergistic anti-inflammatory effects of IL-10 and PSL, and can be used as a macrophage-targeted therapeutic material for inflammation-related diseases, including obesity.

    UR - http://www.scopus.com/inward/record.url?scp=84989308879&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84989308879&partnerID=8YFLogxK

    U2 - 10.1016/j.biomaterials.2016.09.018

    DO - 10.1016/j.biomaterials.2016.09.018

    M3 - Article

    AN - SCOPUS:84989308879

    VL - 110

    SP - 81

    EP - 88

    JO - Biomaterials

    JF - Biomaterials

    SN - 0142-9612

    ER -